Amgen vs Bristol Myers Squibb
AMGN and BMY side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AMGN and BMY compare
Amgen is the larger company, worth 2.0 times as much as Bristol Myers Squibb ($252B against $128B).
On earnings, Bristol Myers Squibb is cheaper: it trades at 13.9× trailing earnings, against 28.9× for Amgen.
Amgen grew revenue faster over the last twelve months (9.1% versus 4.2% for Bristol Myers Squibb).
Amgen keeps more of each dollar of sales as profit, with a net margin of 23.0% compared with 18.5% at Bristol Myers Squibb.
Both pay dividends: Amgen yields 2.1% and Bristol Myers Squibb 4.0%.
Amgen scores higher on the StockData Score (17 against 14 for Bristol Myers Squibb), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AMGN | BMY |
|---|---|---|
| Size and price | ||
| Market cap | $252B | $128B |
| Share price | $466.01 | $62.48 |
| Change, 1 year | 59.7% | 46.7% |
| Change, 5 years | 118% | 5.1% |
| Beta (5Y) | 0.42 | 0.25 |
| Employees | 32K | 33K |
| StockData Score | ||
| Total score | 17 (better) | 14 |
| Valuation score | 0 | 4 (better) |
| Growth score | 5 (better) | 0 |
| Performance score | 6 (better) | 3 |
| Health score | 2 | 2 |
| Dividend score | 4 | 5 (better) |
| Valuation | ||
| P/E | 28.9× | 13.9× (better) |
| P/S | 6.6× | 2.6× (better) |
| P/B | 21.6× | 5.5× (better) |
| EV/EBITDA | 20.9× | 10.0× (better) |
| P/FCF | 24.8× | 13.7× (better) |
| PEG | 5.24 | 2.54 (better) |
| FCF yield | 4.0% | 7.3% (better) |
| Fair value | $334.49 | $87.52 |
| Margin of safety | −39.3% | 28.6% (better) |
| Growth | ||
| Revenue growth (TTM) | 9.1% (better) | 4.2% |
| Revenue growth, 5Y average | 7.6% (better) | 2.5% |
| Net income growth (TTM) | 32.1% | 53.1% (better) |
| EPS growth (TTM) | 31.6% | 52.4% (better) |
| EPS growth, 5Y average | 2.9% | – |
| Profitability | ||
| Gross margin | 69.5% (better) | 69.2% |
| Operating margin | 30.0% | – |
| Net margin | 23.0% (better) | 18.5% |
| FCF margin | 26.7% (better) | 18.6% |
| Return on equity | 91.5% (better) | 44.1% |
| Return on invested capital | 17.6% | – |
| Financial health | ||
| Debt / equity | 4.90 | 1.83 (better) |
| Net debt / EBITDA | 3.07 | 1.92 (better) |
| Interest coverage | 4.3× | – |
| Current ratio | 1.37 | 1.59 (better) |
| Altman Z-score | 2.39 (better) | 2.22 |
| Piotroski F-score | 7 | 8 (better) |
| Dividends and buybacks | ||
| Dividend yield | 2.1% | 4.0% (better) |
| Payout ratio | 60.4% | 55.4% |
| Years of dividend growth | 9 | 16 (better) |
| Dividend growth, 5Y average | 8.0% (better) | 6.2% |
| Shareholder yield | 2.1% | 4.0% (better) |
| Ownership | ||
| Held by institutions | 82.7% | 81.9% |
| Held by insiders | 0.21% | 0.05% |
| Insider net buying, 12 months | −$29.3M | −$2.3M (better) |
| Superinvestors holding | – | 2 |
| Short interest, % of float | 2.6% | 2.2% |
Go deeper
- AMGN stock overview
- AMGN income statement
- AMGN valuation and score
- BMY stock overview
- BMY income statement
- BMY valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.